InVivo Therapeutics Holdings Corp., a development stage company, focuses on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries, peripheral nerve injuries, and other neurotrauma conditions. For spinal cord injuries, the company’s biopolymer-based devices are surgically implanted or injected into the lesion created during traumatic injury, or the ‘primary injury’. The company intends that the biopolymer scaffolding devices would protect the damaged spinal cord by mitigating the progression of ‘secondary injury’ resulting from the body’s inflammatory and immune response to injury, and would promote neuroplasticity, a process where functional recovery (the recovery of motor movement or sensation) might occur through the rerouting of signaling pathways to the spared healthy tissue. The company intends to develop a biocompatible hydrogel for the local release of methylprednisolone to treat acute peripheral nerve injuries and spinal cord injuries and a biocompatible polymer scaffolding device seeded with autologous human neural stem cells to treat acute and chronic spinal cord injuries. Its major product, the biocompatible polymer scaffolding device to treat acute spinal cord injuries, is intended to be regulated by the U.S. Food & Drug Administration as a Class III medical device. The company also intends to develop biocompatible hydrogel devices for use as dural sealants, dural replacements, and as nerve conduits. The company’s biopolymer scaffolding has been designed to prevent and mitigate the cascading inflammatory response or secondary injury and its device is intended to perform four functions, such as fill the necrotic lesion to minimize secondary injury, which might occur by inhibiting cell-cell signaling through inflammatory cytokines; bridge the gap formed by the lesion, providing a matrix designed to promote regrowth and reorganization of neural elements (neurons and neurites); act as a synthetic extracellular matrix, with the goal of promoting survival of surrounding neurons; and reduce scar formation (astrogliosis). The company intends to develop an injectable hydrogel designed to counteract the inflammatory environment that results in peripheral nerve injuries and during a secondary injury from a closed-wound spinal cord injury where further cell death occurs. It intends to develop an extension of the biopolymer scaffolding platform technology to treat both acute closed-wound and chronic spinal cord injury patients by seeding the patient’s own stem cells onto the scaffold and then inserting the scaffold into the injured spinal cord. The scaffold acts as a synthetic extracellular matrix on which cells could be transplanted. This product is intended to counteract the pathophysiology of spinal cord injury by replacing lost cells of the spinal cord and activating endogenous regenerative processes, such as the formation of new synapses and axonal sprouting based on molecules the stem cells produce. Sales and Marketing The company intends to sell its spinal cord injury products through a to-be-established direct sales force for major markets in the U.S and through distributors in foreign markets. Intellectual Property The company obtained a worldwide license (the ‘CMCC License’) to a suite of patents co-owned by Massachusetts Institute of Technology and Children’s Medical Center Corporation (CMCC) covering the use of a range of biopolymers to treat spinal cord injury, and to promote the survival and proliferation of human stem cells in the spinal cord. In addition, they cover the use of biomaterials in combination with growth factors and drugs. The CMCC License covers 11 issued U.S. patents and 3 pending U.S. patents, as well as 34 issued international patents and 23 international patents pending. History InVivo Therapeutics Holdings Corp. was founded in 2005.
invivo therapeutics holdings
One Kendall Square
Cambridge, MA 02139
|No competitor information is available for NVIV.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Post a JobJobs
- Pittsburgh, PA | Carnegie Museums of PittsburghPosted: Dec 09
- New York, NY | JPMorgan ChasePosted: Dec 06
- Alexandria, VA | Mack-sumner CommunicationsPosted: Dec 06
- Detroit, MI | Wayne State UniversityPosted: Nov 26
Sponsored Financial Commentaries
To contact INVIVO THERAPEUTICS HOLDINGS, please visit www.invivotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.